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Abstract
Human metapneumovirus (hMPV) is a recently discovered respiratory pathogen, infecting mainly young children. The
infected patients suffer from influenza like symptoms (ILS). In Israel the virus is mainly circulating in February to March.
Here we report on an increased rate of hMPV infection in the winter season of 2009–10. The 2009–10 infection had
several unique characteristics when compared to previous seasons; it started around January and a large number of
infants were infected by the virus. Genetic analysis based on the viral L and F genes of hMPV showed that only subtypes
A2 and B2 circulated in Israel. Additionally, we have identified a novel variant of hMPV within subgroup A2b, which
subdivide it into A2b1 and A2b2. Finally, we showed that the hMPV infection was detected in the country soon after the
infection with the pandemic influenza virus had declined, that infection with the pandemic influenza virus was dominant
and that it interfered with the infection of other respiratory viruses. Thus, we suggest that the unusual increase in hMPV
infection observed in 2009–10 was due to the appearance of the pandemic influenza virus in the winter season prior to
2009–10.
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Introduction
Human metapneumovirus (hMPV) is a member of the
paramyxoviridae family which also includes respiratory syncytial
virus (RSV), measles virus, and mumps virus [1,2]. The infection
symptoms caused by hMPV are similar to those caused by RSV
and patients infected with hMPV demonstrates symptoms ranging
from upper respiratory tract infection to bronchiolitis and
pneumonia that is often accompanied by high fever, myalgia,
and vomiting [2–7]. It has been suggested that hMPV is
responsible for 5–10% of acute respiratory tract infections in
neonates and children [8–10]. In general, hMPV infections are
mainly observed in young children, in the elderly [11,12] and in
immunocompromised adults [13–16].
hMPV isolates are classified by phylogenetic analysis into two
major genetic lineages termed subtypes A and B and are further
subdivided into four subgroups (A1, A2, B1, and B2) [8,10,17–23].
Subtype A is the most dominant one [8,17,20,23,24]. A recent
report demonstrated the existence of novel sub-lineages within the
hMPV subgroup A2, named A2a and A2b [18,23,25]. Another
recent study demonstrated the existence of various subtypes in the
B2 group [26].
Here we report on an increased rate of hMPV infection in Israel
in the year 2009–10, one year following the appearance of the
pandemic influenza virus. We show that the 2009–10 hMPV
infection had unique characteristics and we report on the
identification of new hMPV subtype that we named A2b2.
Materials and Methods
Ethics
The institutional review board (IRB) of the Sheba Medical
Center approved this research (Helsinki Number 9155-11-SMC).
The work described in this manuscript is a retrospective study
performed on patients samples that were analyzed for the presence
of various viruses as part of the routine tests performed in the
Sheba Medical Center and no extra samples were obtained for this
research. The retrospective analysis performed was anonymous.
Due to all of these reasons informed consent (either written or
verbal) was not required.
Patients and samples
Respiratory clinical samples (nasopharyngeal swabs or aspirates)
were collected from 1635 patients hospitalized at Sheba Medical
Center, Israel, due to respiratory illnesses, during the winter
seasons between November 2007 and May 2010. Samples were
retrospectively tested for the presence of hMPV, influenza viruses
A and B, RSV and Adenovirus using a panel of real-time reverse
transcription-PCR (rRT-PCR) and by real time PCR (for Adeno
only) as previously described [27,28]. In 2009–10 samples were
also tested for the presence of pandemic influenza A(H1N1)pdm09
by real-time PCR using TaqMan chemistry [29].
RNA extraction
Viral genomic RNA was extracted from patients’ sample by
using either High Pure viral RNA extraction kit (Roche
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34750Diagnostics GmbH, Mannheim, Germany) or by using the
NucliSENS easyMAG (BioMerieux, France).
DNA Sequencing
Two different sets of primers were used. The first set of primers
was used to amplify part of the hMPV L (polymerase) gene and
was used for diagnosis of patient clinical samples. Phylogenetic
analysis based on 171-bp long sequence derived from the hMPV L
gene was performed as described in Regev at el. [30]. The second
set of primers was used for DNA sequencing and phylogenetic
analysis amplified a 527-bp fragment of the hMPV F (Fusion)
gene, as described in Carr at el. [26]. RT-PCR was performed
using QIAGEN OneStep RT-PCR kit (QIAGEN GmbH, D-
40724 Hilden, Germany). RT-PCR products were sequenced
using ABI PRISM Dye Deoxy Terminator cycle sequencing kit
(Applied Biosystems, Foster City, CA). Reaction mixtures were
analyzed on Applied Biosystems model 373 DNA automatic
sequencing systems.
Phylogenetic analysis
The SequencherH 5.0 program (Gencodes Corporation, Ann
Arbor, MI) was used to compare the nucleotide sequences.
Phylogenetic trees were prepared by nearest neighbor joint
analysis using Clustal X with 1000 bootstraps and trees were
visualized using TreeView or NJ plot software.
Results
Increased infection of hMPV during 2009–10
Our study was initiated because we observed a dramatic
increase in the proportion of hMPV-infected patients that were
hospitalized at the Sheba Medical Center during the 2009–10
winter season (between January to May). We have therefore
decided to perform a retrospective examination on three winter
seasons: 2007–8, 2008–9 and 2009–10. 1635 nasopharyngeal
swabs or aspirates were collected and tested by qRT-PCR for
hMPV infection. The hospitalized patients suffered from various
symptoms; most of them had fever and cough. Some suffered from
bronchitis and sore/red throat and small percentages of patients
had also pneumonia (Table 1). As shown in figure 1, 15 of the 172
samples (8.7%) that were collected during the 2007–8 season, 58 of
the 528 samples (11%) that were collected during the 2008–9
season and 172 of the 935 samples (18.4%) that were collected
during the 2009–10 season were found to be hMPV positive
(Figure 1). Significant (Chi square test) differences in the rates of
hMPV positive cases were found between the winter seasons of
2009–10 and each of the two previous seasons, 2007–8
(P=0.0027) and 2008–9 (P=0.002), while the differences
observed between 2007–8 and 2008–9 seasons, were not
statistically significant (P=0.48).
Prevalence of hMPV infection in 2009–10
To investigate the reasons for the increase in hMPV infections
we next studied whether the 2009–10 infection manifest unusual
characteristics. We initially examined the time in which infections
with hMPV were detected. The analysis summarizes the percent of
hMPV infected patients that were detected throughout the year.
Normally, hMPV infections are frequent during the months of
February and March. However, in 2009–10 the monthly
distribution of hMPV infections was somewhat different from
the two previous winter seasons. While in the 2007–8 and 2008–9
winter seasons a substantial number of cases were detected in
February till March, in 2009–10 a significant number of
hospitalized patients was already diagnosed in January and the
percentages of hMPV infected patients were doubled (Figure 2).
In 2009–10 infants were primarily infected with hMPV
To further investigate the reasons accounting for the increase in
hMPV infection observed in 2009–10 we investigated the age
distribution of the patients infected in 2009–10 and compared it to
the previous two winter seasons. As can be seen in figure 3, while
in 2007–8 and in 2008–9 the ages of most of the hMPV-infected
individuals range between 1–5 and from 21 and above, in the
Figure 1. Percent of Hospitalized hMPV patients in Israel.
Percent of patients positive for hMPV infections out of patients
diagnosed for respiratory virus infections. The patients were hospital-
ized in the Sheba Medical Center, Israel, and three winter seasons 2007–
10 are presented.
doi:10.1371/journal.pone.0034750.g001
Table 1. Clinical characteristics.
Age (years) Total (%) Fever (%) Cough (%) Bronchitis (%) Pneumonia (%) Sore/Red throat (%)
0–5 47.3 50 47.8 50 66.6 34.7
6–10 10.7 11.4 10.8 0 0 14.3
11–20 5.4 5.7 5.4 0 0 8.2
21–50 19.3 17 18.5 7.1 8.3 28.6
.50 17.2 15.9 17.4 42.9 25 14.3
Total (%) 100 94.6 98.9 30 12.9 52.7
The table shows the ages of the various patients used in this study, the symptoms they suffer from and the percentages of patients in the various age groups that had
these symptoms.
doi:10.1371/journal.pone.0034750.t001
Increased hMPV Infection
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e347502009–10 season, a large proportion of infants (age less than 1 year)
were also infected (Figure 3).
It was previously reported that hMPV infections are associated
with infections with additional viruses [31–33]. We therefore next
investigated whether increased percentages of patients co-infected
with several viruses will be observed in 2009–10. We found that
while in 2007–8 and in 2008–9 13.3% and 12%, respectively, of
the patients were co-infected with hMPV and additional viruses, in
2009–10 around 20% were co-infected with several viruses (data
not shown). This difference however was not statistically
significant. Thus, in 2009–10 hMPV infection was noticed in
large percentages of patients, the infection was detected early than
usual and infants were those who were primarily infected.
Genetic analysis of the hMPV circulating strains
To test whether the unusual characteristics and the increase
percentages of hMPV infection observed in 2009–10 was due to
infection with a particular strain of hMPV that was present in the
country during this year, we determine the hMPV types that
circulated in Israel between 2007–10, by using RT-PCR. A
portion of the L gene of hMPV [30] was sequenced in randomly
selected clinical samples. As shown in figure 4, no major
differences were observed in the circulating virus types, or
subtypes in all 3 years of studied. Interestingly, the only two
subtypes that were detected in Israel during these 3 seasons were
A2 and B2, while the A1 and B1 subtypes were not detected. A
phylogenetic analysis based on the F gene was used to determine
whether new subtypes could be detected in Israel in the winter
season of 2009–10. Fourteen arbitrary selected samples (obtained
from both children and adults) that were obtained between the
years 2007–10, were sequenced and as shown in figure 5, indeed
only the A2 and the B2 subtypes were found, confirming our
above observations (Figure 4). The B2b subtypes that was recently
identified in Ireland [26], was also found in Israel (Figure 5).
However, interestingly, new hMPV sub-lineages named A2b2
which splits the A2b subtype into two groups: A2b1 and A2b2, was
identified by the phylogenetic analysis (Figure 5). This new sub-
lineages however were already present in 2008–9 and therefore it
is probably not the cause of the hMPV increase that occurred in
2009–10.
Figure 2. The hMPV infection in 2009–10 is observed early than usual. Precent of hMPV infected patients throughout the year. The figure
shows themonthly distribution of hMPV positive cases diagnosed at the Central Virology Laboratory between November 2007 and May 2010.
doi:10.1371/journal.pone.0034750.g002
Figure 3. A large number of infants were infected with hMPV in 2009–10. The figure shows the percentages of the age distribution of the
hMPV positive cases diagnosed at the Central Virology Laboratory between November 2007 and May 2010.
doi:10.1371/journal.pone.0034750.g003
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Since no differences were observed between the various hMPV
strains that circulated in the country in 2010 versus previous years
we conclude that other factors are responsible for the increased
hMPV infections observed in 2010.
In April 2009 a new pathogen; the H1N1 pandemic influenza
virus had circulated in the country and around the world. We
therefore decided to test whether the appearance of the pandemic
influenza virus in 2009 might have been responsible for the
unusual characteristics of the hMPV infection observed in 2010.
For that we have analyzed the incidence rates of laboratory
detections of seasonal influenza, pandemic influenza and hMPV
infections throughout the study period. As can be seen in figure 6,
in 2007–8 and in 2008–9 the hMPV infections were observed
almost concomitantly with seasonal influenza infections (Figure 6).
A major change had occurred in April 2009 with the appearance
of the pandemic influenza virus. The virus was present in the
country until March 2010 (from January till March only few cases
of pandemic influenza virus infections were detected) and two
picks of infection were noted around June and around November
2009. Furthermore, the pandemic infection (H1N1) was dominant
over other respiratory viruses, as infections with seasonal influenza
(Figure 6) and other respiratory viruses (such as RSV, data not
shown) could hardly be detected. Interestingly, the infection
incidence of the pandemic influenza virus declined immediately
prior to the appearance of the hMPV infections (Figure 6).
Discussion
We report here on an increase hMPV infection that occurred in
Israel in the winter season of 2009–10. In the years prior to 2009–
10, the proportions of hMPV infections among hospitalized
Figure 4. The A2 subtype is the dominant hMPV virus
circulating in the country. The figure shows the number of cases
(arbitrary selected) infected either with the A2 or the B2 subtypes of
hMPV during the 3 winter seasons, from 2007–10. The various subtypes
were determined by sequencing the L gene.
doi:10.1371/journal.pone.0034750.g004
Figure 5. Identification of new hMPV subtype. The figure shoe a phylogenetic tree that was constructed based on the nucleotide sequences
(111 bp) of the Fusion gene (F protein).
doi:10.1371/journal.pone.0034750.g005
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winter of 2009–10, 18.4% of the patients were infected with
hMPV. It should also be noted that we investigated here
hospitalized patients only and thus the increased hMPV infection
we observed might be only be the tip of the iceberg, given that
most respiratory virus infections are mild (though not necessarily
asymptomatic).
The hMPV infection in 2009–10 had several special properties; it
appeared earlier than usual and a large proportion of infants less
than 1 year old were infected. Infections with hMPV are frequently
associated with a co-infection with another virus [31–33].
Indeed, around 20% of the hMPV infected patients in 2009–10
were co-infected with additional virus however this was not
significantly different from previous years. We further discovered
a new sub-lineage named A2b2. This observation, although
interesting, cannot explain the hMPV morbidity observed in
2009–10, as this sub-lineage was already present in the population
in the winter season of 2008–9 and most of the patients in 2009–10
were diagnosed to have the A2a1 subtype.
What could therefore be the reason for the increased hMPV
infection? One possible explanation might be the appearance of
the new pandemic influenza virus in 2009 [29] which circulated in
Israel, having two infection peaks in June and in November 2009
[35]. Interestingly, we show that infection with the pandemic
influenza virus was dominant over other respiratory viruses and
that little or no other respiratory viruses, such as influenza and
RSV, were active when the pandemic influenza virus was present
(Figure 6 and data not shown). Strikingly, hMPV infections were
noticed soon after the infection with the pandemic influenza virus
had declined. Our assumption is that the pandemic influenza
infection that emerged in the country in 2009 was dominant and
thus it interfered with the infection of other respiratory viruses.
Thus, once it declined, hMPV infections, which occur roughly at
that period, were increased. We therefore suggest that it might be
useful to vaccinate the population during infection of pandemic
viruses not only against the circulating virus but also against
additional respiratory viruses because, as we shown here, following
pandemic influenza infections increased proportion of patients
(especially young children) might be at danger of being infected
with other respiratory viruses such as hMPV.
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